Status:

COMPLETED

Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Native and Valve in Valve Aortic Valve Failure

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

Background: TAVR is a common therapy for people with heart problems. It stands for transcatheter aortic valve replacement, TAVR can be a better option than surgery. But it isn t safe for everyone. It...

Detailed Description

Transcatheter aortic valve replacement (TAVR) is an option to treat aortic valve stenosis or failure of a surgically implanted tissue valve. Sometimes TAVR displaces the diseased aortic valve leaflets...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Adults age greater than or equal to 21 years
  • High or extreme risk of surgical aortic valve replacement according to the local multidisciplinary heart team
  • Undergoing TAVR for valve-in-valve or native aortic valve failure ( on-label TAVR)
  • Deemed likely to suffer coronary artery obstruction from TAVR according to multidisciplinary heart team
  • Concurrence of the study eligibility committee
  • EXCLUSION CRITERIA:
  • Subjects unable to consent to participate, unless the subject has a legally authorized representative
  • Excessive target aortic leaflet calcification or masses on baseline CT
  • Survival despite successful procedure expected \< 12 months
  • Planned concurrent valve intervention in the same setting (such as transcatheter mitral valve therapy or paravalvular leak therapy)
  • Subjects unwilling to participate or unwilling to return for study follow-up activities.
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures

Exclusion

    Key Trial Info

    Start Date :

    February 14 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 22 2019

    Estimated Enrollment :

    31 Patients enrolled

    Trial Details

    Trial ID

    NCT03381989

    Start Date

    February 14 2018

    End Date

    August 22 2019

    Last Update

    March 18 2021

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Medstar Washington Hospital Center

    Washington D.C., District of Columbia, United States, 20010

    2

    Emory University Hospital

    Atlanta, Georgia, United States, 30322

    3

    Henry Ford Hospital

    Detroit, Michigan, United States, 48202

    4

    University of Washington

    Seattle, Washington, United States, 98195

    Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation | DecenTrialz